Mankind Pharma Limited reported its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025, showing a steady performance with a profit after tax of ₹414 crore, a 9.5% increase from ₹378 crore in the corresponding quarter of the previous year. The company’s revenue from operations reached ₹3,567 crore for the current quarter, representing an 11.5% growth compared to ₹3,199 crore in the same period last year. On a sequential basis, revenue experienced a slight decrease of 3.5% from ₹3,697 crore in the previous quarter, while profit after tax declined by 20.4% from ₹520 crore.

Financial Result Analysis (Q3 FY26) | Metric | Current Quarter (Q3 FY26) | Previous Quarter (Q2 FY26) | Corresponding Quarter (Q3 FY25) | % Change (QoQ) | % Change (YoY) | | :— | :— | :— | :— | :— | :— | | Revenue (₹ Cr) | 3,567 | 3,697 | 3,199 | -3.5% | +11.5% | | Profit After Tax (₹ Cr) | 414 | 520 | 378 | -20.4% | +9.5% |

Mankind Pharma is one of India’s leading pharmaceutical companies, focusing on a diverse range of pharmaceutical formulations across acute and chronic therapeutic areas, as well as several popular consumer healthcare brands. In 2025, the company has actively expanded its portfolio through strategic moves, including the integration of Bharat Serums and Vaccines Limited (BSV) and the acquisition of its Women Health Rx Portfolio for ₹797 crore to strengthen its position in the specialty segment. Recent updates from November 2025 highlight regulatory developments where the CDSCO advised the company to conduct Phase I clinical trials in India for its Sintilimab Injection before proceeding to Phase III. The company continues to maintain a strong domestic presence with an 18,000+ field force and is ranked #1 in prescriptions in the Indian Pharmaceutical Market. Notable investors in the company’s history include ChrysCapital and Capital Group, although reports from late 2024 and 2025 indicate significant stake divestments by these private equity firms as the company transitioned into a more mature public entity.